Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging Era of universal antiretroviral therapy use

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Jinno, Sadao ^a,d   Anker, Bryan ^a   Kaur, Parveen ^a   Bristow, Claire C ^b   Klausner, Jeffrey D ^c  

^a AIDS HEALTHCARE FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

Benzathine penicillin; HIV; Serological failure; Syphilis

Indexed keywords

BENZATHINE PENICILLIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; REAGIN TEST; REINFECTION; SYPHILIS; SYPHILIS SEROLOGY; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PENICILLIN G BENZATHINE; RETROSPECTIVE STUDIES; SEROLOGIC TESTS; SYPHILIS; TREATMENT OUTCOME;

EID: 84890899013     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-605     Document Type: Article

References (21)

1. 2011 CDC Sexually Transmitted Diseases Surveillance http://www.cdc.gov/std/stats11/syphilis.htm.
2. Gonzalez-Lopez JJ, Guerrero ML, Lujan R, Tostado SF, de Gorgolas M, Requena L. Factors determining serologic response to treatment in patients with syphilis. Clin Infect Dis 2009, 49(10):1505-1511. 10.1086/644618, 19842977.
3. Manavi K, McMillan A. The outcome of treatment of early latent syphilis and syphilis with undetermined duration in HIV-infected and HIV-uninfected patients. Int J STD AIDS 2007, 18(12):814-818. 10.1258/095646207782717018, 18073011.
4. Dowell D, Polgreen PM, Beekmann SE, Workowski KA, Berman SM, Peterman TA. Dilemmas in the management of syphilis: a survey of infectious diseases experts. Clin Infect Dis 2009, 49(10):1526-1529. 10.1086/644737, 19845476.
5. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2010, 59(RR-12):1-110.
6. Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008, 47(2):258-265. 10.1086/589295, 2562285, 18532887.
7. Knaute DF, Graf N, Lautenschlager S, Weber R, Bosshard PP. Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis 2012, 55(12):1615-1622. 10.1093/cid/cis757, 3501331, 22955437.
8. Sena AC, Wolff M, Martin DH, et al. Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis. Clin Infect Dis 2011, 53(11):1092-1099. 10.1093/cid/cir671, 3205200, 21998287.
9. Hook EW, Behets F, Van Damme K, et al. A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis. J Infect Dis 2010, 201(11):1729-1735. 10.1086/652239, 20402591.
10. Hook EW, Martin DH, Stephens J, Smith BS, Smith K. A randomized, comparative pilot study of azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 2002, 29(8):486-490. 10.1097/00007435-200208000-00010, 12172535.
11. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. N Engl J Med 2005, 353(12):1236-1244. 10.1056/NEJMoa044284, 16177249.
12. Raichle ME, Kutt H, Louis S, McDowell F. Neurotoxicity of intravenously administered penicillin G. Arch Neurol 1971, 25(3):232-239. 10.1001/archneur.1971.00490030058006, 4951946.
13. Neftel KA, Walti M, Spengler H, et al. Neutropenia after penicillins: toxic or immune-mediated?. Klin Wochenschr 1981, 59(16):877-888. 10.1007/BF01721921, 7278079.
14. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997, 337(5):307-314. 10.1056/NEJM199707313370504, 9235493.
15. Dionne-Odom J, Karita E, Kilembe W, et al. Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda. Clin Infect Dis 2013, 56(12):1829-1837. 10.1093/cid/cit146, 23487377.
16. Farhi D, Benhaddou N, Grange P, et al. Clinical and serologic baseline and follow-up features of syphilis according to HIV status in the post-HAART era. Medicine (Baltimore) 2009, 88(6):331-340. 10.1097/MD.0b013e3181c2af86, 19910747.
17. Gourevitch MN, Selwyn PA, Davenny K, et al. Effects of HIV infection on the serologic manifestations and response to treatment of syphilis in intravenous drug users. Ann Intern Med 1993, 118(5):350-355. 10.7326/0003-4819-118-5-199303010-00005, 8094280.
18. Hutchinson CM, Hook EW, Shepherd M, Verley J, Rompalo AM. Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med 1994, 121(2):94-100. 10.7326/0003-4819-121-2-199407150-00003, 7912483.
19. Janier M, Chastang C, Spindler E, et al. A prospective study of the influence of HIV status on the seroreversion of serological tests for syphilis. Dermatology 1999, 198(4):362-369. 10.1159/000018149, 10449935.
20. Cox DL, Akins DR, Porcella SF, Norgard MV, Radolf JD. Treponema pallidum in gel microdroplets: a novel strategy for investigation of treponemal molecular architecture. Mol Microbiol 1995, 15(6):1151-1164. 10.1111/j.1365-2958.1995.tb02288.x, 7623668.
21. Magnuson HJ, Eagle H, Fleischman R. The minimal infectious inoculum of Spirochaeta pallida (Nichols strain) and a consideration of its rate of multiplication in vivo. Am J Syph Gonorrhea Vener Dis 1948, 32(1):1-18.